Association of KRAS and EGFR Mutations With Survival in Patients With Advanced Lung AdenocarcinomasJOHNSON, Melissa L; SIMA, Camelia S; CHAFT, Jamie et al.Cancer. 2013, Vol 119, Num 2, pp 356-362, issn 0008-543X, 7 p.Article

Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancersCHAFT, Jamie E; REKHTMAN, Natasha; SIMA, Camelia S et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 4, pp 931-934, issn 0344-5704, 4 p.Article

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial DesignCHAFT, Jamie E; OXNARD, Geoffrey R; SIMA, Camelia S et al.Clinical cancer research (Print). 2011, Vol 17, Num 19, pp 6298-6303, issn 1078-0432, 6 p.Article

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung AdenocarcinomasARCILA, Maria E; CHAFT, Jamie E; NAFA, Khedoudja et al.Clinical cancer research (Print). 2012, Vol 18, Num 18, pp 4910-4918, issn 1078-0432, 9 p.Article

Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR GeneRIZVI, Naiyer A; RUSCH, Valerie; FLORES, Raja et al.Clinical cancer research (Print). 2011, Vol 17, Num 10, pp 3500-3506, issn 1078-0432, 7 p.Article

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumabHELLMANN, Matthew D; CHAFT, Jamie E; KRUG, Lee M et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 2, pp 453-461, issn 0344-5704, 9 p.Article